Indomethacin decreases EP2 prostanoid receptor expression in colon cancer cells

Biochemical and Biophysical Research Communications

Volumn 359, Issue 3, 2007, Pages 568-573

  Fujino, Hiromichi ^a   Chen, Xiao bo ^b   Regan, John W ^b   Murayama, Toshihiko ^a  

^a CHIBA UNIVERSITY   (Japan)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

cAMP; EP2 receptor; G protein coupled receptors; Indomethacin; LS174T cells; NSAIDs; PGE2; Prostaglandin E2

Indexed keywords

CYCLIC AMP; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PROSTANOID RECEPTOR;

ARTICLE; BINDING AFFINITY; CANCER CELL; COLON CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; WHOLE CELL;

CELL LINE, TUMOR; COLONIC NEOPLASMS; CYCLIC AMP; DINOPROSTONE; DOWN-REGULATION; FORSKOLIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOMETHACIN; RECEPTORS, PROSTAGLANDIN E; RNA, MESSENGER;

EID: 34250211822     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.05.145     Document Type: Article

References (24)

1. Sugimoto Y., and Narumiya S. Prostaglandin E receptors. J. Biol. Chem. 282 (2007) 11613-11617
2. Regan J.W. EP2 and EP4 prostanoid receptor signaling. Life Sci. 74 (2003) 143-153
3. Fujino H., and Regan J.W. EP4 prostanoid receptor coupling to a pertussis toxin-sensitive inhibitory G protein. Mol. Pharmacol. 69 (2006) 5-10
4. Brown J.R., and DuBois R.N. COX-2: a molecular target for colorectal cancer prevention. J. Clin. Oncol. 23 (2005) 2840-2855
5. Δ716 knockout mice. Nat. Med. 7 (2001) 1048-1051
6. Mutoh M., Watanabe K., Kitamura T., Shoji Y., Takahashi M., Kawamori T., Tani K., Kobayashi M., Maruyama T., Kobayashi K., Ohuchida S., Sugimoto Y., Narumiya S., Sugimura T., and Wakabayashi K. Involvement of prostaglandin E receptor subtype EP4 in colon carcinogenesis. Cancer Res. 62 (2002) 28-32
7. Segditsas S., and Tomlinson I. Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene 25 (2006) 7531-7537
8. 2. J. Biol. Chem. 277 (2002) 2614-2619
9. Patrono C., Patrignani P., and Garcia Rodriguez L.A. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J. Clin. Invest. 108 (2001)
10. Tegeder I., Pfeilschifter J., and Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J. 15 (2001) 2057-2072
11. Shoji Y., Takahashi M., Kitamura T., Watanabe K., Kawamori T., Maruyama T., Sugimoto Y., Negishi M., Narumiya S., Sugimura T., and Wakabayashi K. Downregulation of prostaglandin E receptor subtype EP3 during colon cancer development. Gut 53 (2004) 1151-1158
12. Fujino H., and Regan J.W. FP prostanoid receptor activation of a T-cell factor/β-catenin signaling pathway. J. Biol. Chem. 276 (2001) 12489-12492
13. 2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signaling-regulated kinases. J. Biol. Chem. 278 (2003) 12151-12156
14. 2 stimulates the β-catenin/T cell factor-dependent transcription in colon cancer. J. Biol. Chem. 280 (2005) 26565-26572
15. Sheng H., Shao J., Washington M.K., and DuBois R.N. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J. Biol. Chem. 276 (2001) 18075-18081
16. Brabletz T., Jung A., Reu S., Porzner M., Hlubek F., Schughart L.A., Knuechel R., and kirchner T. Variable β-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc. Natl. Acad. Sci. USA 98 (2001) 10356-10361
17. 2 administration. Carcinogenesis 24 (2003) 985-990
18. Clevers H. Colon cancer - understanding how NSAIDs work. N. Engl. J. Med. 354 (2006) 761-763
19. s-axin-β-catenin signaling axis. Science 310 (2005) 1504-1510
20. Futaki N., Takahashi S., Yokoyama M., Arai I., Higuchi S., and Otomo S. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 47 (1994) 55-59
21. Shao J., Sheng H., Inoue H., Morrow J.D., and DuBois R.N. Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells. J. Biol. Chem. 275 (2000) 33952-33956
22. 2 receptor, CRTH2. J. Immunol. 168 (2002) 981-985
23. Lehmann J.M., Lenhard J.M., Oliver B.B., Ringold G.M., and Kliewer S.A. Peroxisome proliferators-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 272 (1997) 3406-3410
24. 2 receptor subtype EP2 by PPARγ ligands inhibits human lung carcinoma cell growth. Biochem. Biophys. Res. Commun. 314 (2004) 1093-1099